Edwards Lifesciences Is Betting the House on Transcatheter Valves — And the Market Is Rewarding the Focus

After offloading Critical Care to BD for $4.2B, Edwards is a pure-play structural heart company with 60%+ U.S. TAVR market share. TMTT is the growth engine now, up 52% YoY in Q1 2026, and a favorable CMS coverage proposal could blow the addressable market wide open.

EW · Health Care · July 16, 2026

S&P 500 Position

Edwards sits in the Health Care Equipment space alongside larger players like Abbott, Medtronic, and Boston Scientific. Within structural heart specifically, it is the clear leader. Abbott's MitraClip competes directly in the mitral edge-to-edge repair market against PASCAL, and Medtronic's Evolut is the primary TAVR rival. Edwards' $50B market cap is roughly one-third of Medtronic's, but it commands significantly higher margins and growth rates due to its focused portfolio.

Index Weight: ~0.10% | Rank: Approximately 150–180 in the S&P 500 by market cap

Company Overview

Edwards Lifesciences is the dominant force in transcatheter aortic valve replacement, holding 60–65% of the U.S. TAVR market and 55–60% globally with its SAPIEN 3 Ultra RESILIA platform. The company completed a strategic transformation in September 2024 by selling its Critical Care segment to Becton Dickinson for $4.2 billion, crystallizing a $3.3 billion gain and leaving Edwards as a pure-play structural heart company across three product lines: TAVR, Transcatheter Mitral and Tricuspid Therapies (TMTT), and Surgical. The bet is that focus yields faster innovation velocity and deeper clinical evidence generation — and Q1 2026 results support the thesis, with total revenue up 16.7% to $1.65 billion. The competitive landscape is shifting in Edwards' favor. A European competitor exited the TAVR market, slightly boosting Edwards' global share in Q1 2026. More consequentially, on July 4, 2026, CMS issued a new TAVR National Coverage Determination proposal that Evercore ISI analysts called "uber bullish" — a potential expansion of Medicare reimbursement that could accelerate procedure volumes in the U.S. Meanwhile, the TMTT franchise is scaling rapidly with three distinct product platforms (PASCAL edge-to-edge repair, EVOQUE tricuspid replacement, SAPIEN M3 mitral replacement), and management is targeting $2 billion in TMTT revenue by 2030, up from $550 million in FY 2025. Edwards sits on $2.4 billion in cash against $600 million in debt and carries no dividend obligation, directing capital instead toward share repurchases ($500 million ASR completed in Q1 2026) and R&D. The PROGRESS trial studying TAVR in moderate aortic stenosis — a population roughly double the current addressable market — represents the single largest catalyst on the horizon. If that trial reads out positively, the structural heart TAM could fundamentally re-rate.

Products & Revenue

Edwards generates revenue from three product groups, all centered on heart valve disease. TAVR is the cash cow, contributing nearly three-quarters of revenue via the SAPIEN family of balloon-expandable transcatheter aortic valves. TMTT is the high-growth segment, now crossing $175 million per quarter on the back of PASCAL, EVOQUE, and the newly FDA-approved SAPIEN M3. Surgical rounds out the portfolio with traditional open-heart valve products including RESILIA tissue valves and repair annuloplasty rings. The mix is deliberately shifting toward transcatheter approaches, reflecting both clinical evidence favoring less-invasive procedures and higher ASPs in the transcatheter categories.

Transcatheter Aortic Valve Replacement (TAVR) (72.6%): The SAPIEN 3 Ultra RESILIA valve platform, delivered via transfemoral catheter for aortic stenosis patients across all risk categories. Edwards holds 60–65% U.S. market share and competes primarily against Medtronic's Evolut family.

Transcatheter Mitral and Tricuspid Therapies (TMTT) (10.6%): Three distinct platforms: PASCAL edge-to-edge repair for mitral/tricuspid regurgitation, EVOQUE tricuspid valve replacement, and SAPIEN M3 transseptal mitral valve replacement (FDA-approved December 2025). Grew 51.9% YoY in Q1 2026.

Surgical (16.8%): Traditional open-heart surgical valves including the INSPIRIS RESILIA aortic valve and mitral/tricuspid repair products. Steady mid-single-digit grower serving patients where open surgery remains the standard of care.

Based on Q1 2026 10-Q filing (SEC). FY 2025 mix was similar: TAVR 74.0%, Surgical 17.0%, TMTT 9.1%.

Leadership

Bernard J. Zovighian

CEO since 2023. Zovighian became CEO in May 2023 after serving as Edwards' president and running the TMTT business unit. He architected the Critical Care divestiture and is driving the company's pure-play structural heart strategy, including the $2 billion TMTT revenue target by 2030. His operational background in building the TMTT franchise from scratch gives him direct product-level credibility.

Theodora ('Doretta') Mistras, Chief Financial Officer: Joined in 2026 from Viatris, bringing over 20 years of healthcare finance experience including investment banking at Citigroup and Goldman Sachs. Overseeing capital deployment of the $4.2B Critical Care sale proceeds.

Larry Wood, Corporate VP, TAVR: Leads the $4.5B+ TAVR franchise, managing the SAPIEN platform's global rollout and the PROGRESS trial for moderate aortic stenosis — Edwards' largest TAM expansion opportunity.

Daveen Chopra, Corporate VP, Transcatheter Mitral and Tricuspid Therapies: Runs the fastest-growing business unit at Edwards, overseeing commercial scaling of PASCAL, EVOQUE, and SAPIEN M3 across U.S. and European markets.

Donald E. Bobo Jr., Corporate VP, Strategy & Corporate Development: Leads Edwards' M&A and strategic planning function, instrumental in the BD Critical Care transaction and ongoing portfolio optimization.

The AI Angle

AI Lives in the Spun-Off Unit, Not the Core

Edwards Lifesciences' most natural AI play — smart patient monitoring powered by continuous hemodynamic data — was sold to BD along with the Critical Care segment in September 2024. The company explicitly cited giving Critical Care the flexibility to develop AI-powered smart patient monitoring solutions as a rationale for the divestiture. What remains at Edwards is a structural heart company whose AI applications are narrower and earlier-stage. As of Q1 2024, Edwards held 11 AI-related patents covering hemodynamic data analysis, contactless physiological monitoring, and nociception detection. These patents largely originated from the Critical Care business and their ongoing relevance to post-divestiture Edwards is unclear. On the product side, there is no publicly disclosed AI feature embedded in SAPIEN, PASCAL, EVOQUE, or SAPIEN M3 valve platforms. The transcatheter valve business is fundamentally a precision-manufactured implant business, not a software platform. Internally, Edwards has adopted Microsoft Copilot for process automation and is exploring generative AI for marketing asset creation. These are operational efficiency plays, not product differentiators. The company has not disclosed dedicated AI research teams, ML engineering headcount, or partnerships with AI infrastructure providers beyond Microsoft's enterprise tools. The honest assessment: Edwards' AI strategy is peripheral to its core business. The company's competitive moat is built on clinical evidence (PARTNER trials, PROGRESS), materials science (RESILIA tissue treatment), and procedural training infrastructure — not algorithmic differentiation. This is not a negative signal; it reflects the reality that transcatheter valve implantation is a mechanical engineering and clinical evidence problem, not an AI problem. Investors looking for AI exposure in medtech should look at Edwards' former Critical Care unit (now inside BD) or competitors like Medtronic with broader digital surgery platforms.

Financial Snapshot

Revenue (TTM): $6.3B — TTM ending March 31, 2026 | Net Income: $1.1B net income (TTM, continuing operations)

Margins: Gross 78.0%, operating 29.0%, net 17.3% (all Q1 2026)

Edwards is a high-margin, capital-light medical device business generating $450M+ in quarterly operating cash flow. Capital allocation is entirely directed at buybacks ($500M ASR in Q1 2026, $1.5B remaining authorization) and R&D — no dividend. Management raised FY 2026 guidance to $6.5–$6.9B revenue with $2.95–$3.05 adjusted EPS, implying acceleration from FY 2025's $6.07B. The 78% gross margin reflects the pricing power of a dominant position in a procedure where switching costs are measured in patient outcomes, not dollars.

1-Year Performance

Trading at $87.84, up 15.4% YoY — solid but trailing the broader medtech rally driven by GLP-1 and AI-in-healthcare hype.

EW shares dipped 3.1% on July 14–15 before recovering on bullish analyst actions from Mizuho (PT $105) and Truist (PT $95). The July 4 CMS TAVR coverage proposal was a 3% catalyst. The stock is trading roughly 10% below the average analyst price target of $97.48, with the Q2 2026 earnings report on July 23 as the next catalyst. Market consensus expects $0.73 EPS on $1.66–$1.74B revenue.

Recent News

Fun Fact: The RESILIA tissue used in Edwards' SAPIEN 3 Ultra and INSPIRIS surgical valves undergoes a proprietary treatment that permanently caps free aldehyde groups in bovine pericardial tissue — the primary mechanism behind calcification-driven valve degeneration. This single materials science innovation is what allows Edwards to claim potential durability advantages over competitors and is protected by a thicket of process patents. The company originally developed the treatment for its surgical valves, then migrated it to the transcatheter platform — a rare example in medtech of a legacy surgical technology improving a disruptive catheter-based successor rather than being cannibalized by it.